Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended) An antagonist of prostaglandin F2 receptor comprising an amino acid sequence selected from the group consisting of ILGHRDYK (PCP-8; SEQ ID NO:1); ILAHRDYK (PCP-13.7, SEQ ID NO:4); ILGFRDYK (PCP-13.11; SEQ ID NO:5); ILGHKDYK (PCP-13.13; SEQ ID NO:6); ILGHRNYK (PCP-13.14; SEQ ID NO:7); ILGHQDYK (PCP-13.18; SEQ ID NO:8); ILGHRDY-amide (PCP-13.20; SEQ ID NO:9); ILGHRDYK-amide (PCP-13.21; SEQ ID NO:1); ILGWRDYK (PCP-13.22; SEQ ID NO:10); and ILGXRDYK (PCP-13.24; SEQ ID NO:11)~~; and SNVLCSIF (PCP-15; SEQ ID NO:12)~~, wherein X is cyclohexyl alanine.

Claim 2 (currently amended) A peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1 and 4 to 11~~12~~ and wherein said amino acid sequence contains L- and/or D-amino acids~~, an~~ and the amino acid sequence ~~with~~ has at least about ~~90%~~ 75 % homology to SEQ ID NO 1 and 4 to 11~~12~~, wherein said peptide is a prostaglandin F2 receptor antagonist.

Claim 3 (previously amended) A method for preventing premature delivery of fetus, which comprises the step of administering to a female in need of such treatment a therapeutically effective amount of the antagonist of claim 1.

Claim 4 (previously amended) A method for preventing and/or treating dysmenorrhea comprising the step of administering to a female in need of such treatment a therapeutically effective amount of the antagonist of claim 1.

Claim 5 (currently amended) A pharmaceutical composition containing at least one antagonist of claim 1, mixture thereof, in association with a pharmaceutically acceptable carrier.

Claim 6 (withdrawn).

Claim 7 (withdrawn).

Claim 8 (cancelled).

Claim 9 (cancelled).

Claim 10 (New) A method for reducing uterine contraction comprising the step of administering to a female in need of such treatment a therapeutically effective amount of the antagonist of claim 1.